Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ketamine for treatment-resistant depression
ACTRN12621000429853Phase 2Terminated
- Sponsor
- Thompson Institute
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in treatment-resistant depression (TRD), sponsored by Thompson Institute. Primary endpoints: Clinician-rated depressive symptomatology and Participant-rated depression symptoms. Started Mar 2021; status: terminated.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on ACTRN12621000429853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000429853.